Clinical trials · Baltimore, MD
Non-Hodgkin Lymphoma clinical trials in Baltimore
We’re tracking 25 recruiting non-hodgkin lymphoma studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Baltimore, MarylandAges 6 months–30 years - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Baltimore, MarylandAges 1–21 - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Baltimore, MarylandAges Any age - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Baltimore, MarylandAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Baltimore, MarylandAges 18 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT01676805Recruiting
Collecting tissue samples for lymphoma research
This study collects leftover tissue samples from patients with or without lymphoma to help researchers better understand lymph system cancers. It may be an option if you are already having a biopsy or surgery.
Bethesda, MarylandAges 18 years+ - NCT04002947RecruitingPhase 2
Acalabrutinib with chemo for untreated aggressive B-cell lymphoma
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
Bethesda, MarylandAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bethesda, MarylandAges 18 years+ - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT00923442Enrolling by invitation
Study of blood cancers’ biology using stored or new tissue
This trial studies how different blood cancers and early (pre-cancer) blood conditions work, using tumor/blood tissue samples. It may help researchers learn more about disease biology for future treatments, with little to no extra risk if samples come from routine care.
Bethesda, MarylandAges 1–120 - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT01087333Recruiting
Share blood samples to help study blood cancers and treatments
This study collects human samples (like blood or other specimens) to learn more about hairy cell leukemia and other leukemias. It also helps researchers develop new lab-made immune-based medicines for cancer treatment.
Bethesda, MarylandAges 18 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT02682667Recruiting
Providing blood samples for cancer immunotherapy research
This study collects and stores blood/tissue samples (called biospecimens) to support immunotherapy research at the cancer center. If you may qualify, your samples help researchers test new immune-based cancer treatments.
Bethesda, MarylandAges 18–120 - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Bethesda, MarylandAges 18 years+ - NCT05389423RecruitingPhase 1
Pomalidomide plus chemotherapy for HIV-related lymphoma
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Bethesda, MarylandAges 18–120 - NCT07652580Recruiting
Toxins, immunity, and B-cell lymphoma
This study looks at how exposure to toxins might affect your immune system if you have B-cell non-Hodgkin lymphoma. You'll provide blood and skin samples, plus have your genes sequenced, to help researchers find links between environmental exposures and lymphoma.
Bethesda, MarylandAges 4 years+ - NCT07055477RecruitingPhase 1
CCR4 CAR T cells for T-cell lymphoma
This trial tests a new immunotherapy that targets a protein called CCR4 on certain T-cell lymphomas. The treatment uses your own immune cells, modified to find and attack cancer cells, and may help when other treatments have stopped working.
Bethesda, MarylandAges 18–120 - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Washington D.C., District of ColumbiaAges 1–30
Hear when a new Non-Hodgkin Lymphoma trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Non-Hodgkin Lymphoma trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting non-hodgkin lymphoma studies listed above.
- National Institutes of Health Clinical Center · 11 studies
- Children's National Medical Center · 3 studies
- Johns Hopkins University · 3 studies
- MedStar Georgetown University Hospital · 2 studies
- National Cancer Institute (NCI) · 2 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 2 studies
- University of Maryland Medical Center · 2 studies
- Akero Clinical Study Site
What taking part in a non-hodgkin lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting non-hodgkin lymphoma studies in Maryland.
Common questions
- Are there non-hodgkin lymphoma clinical trials near Baltimore?
- Yes. We're currently tracking 25 recruiting non-hodgkin lymphoma studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non-hodgkin lymphoma study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non-hodgkin lymphoma studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.